Heru, which is building a tool that uses AI and commercial AR/VR headsets to diagnose eye conditions and vision loss, raises $30M Series A led by D1 Capital
Context & Ripple Effects
Heru's $30M Series A, led by D1 Capital, puts it in a funding lineage that ophthalmology AI diagnostics has been building for years: IDx's $33M Series A in 2018 grew into Digital Diagnostics' $75M Series B by 2022, and Eyenuk followed with a $26M Series A for diabetic retinopathy screening.
What distinguishes Heru is the delivery model — AI diagnostic software running on commercial, off-the-shelf AR/VR headsets rather than dedicated clinic equipment — and D1's appetite is clearly not one-off, since the same firm led PathAI's $165M Series C for AI disease diagnosis within the same week.
First-order effects
- Heru gains the capital to take its headset-based eye diagnostic from development toward clinical deployment, with D1 Capital now holding positions in two AI diagnostics companies funded days apart.
- Heru's AR/VR approach enters a category where Digital Diagnostics and Eyenuk have already raised successive rounds, giving the space three well-capitalized players with distinct technical routes.
Second-order effects
- Digital Diagnostics and Eyenuk now compete against a rival whose hardware cost structure relies on consumer AR/VR headsets rather than purpose-built diagnostic devices, pressuring the category toward cheaper deployment models.
- Investors watching IDx's Series A-to-Series B trajectory have a template for how far ophthalmology AI companies can scale, which supports follow-on funding for the whole cohort rather than just the leader.
Third-order effects
- If the pattern holds, AI diagnostics consolidates around platform-style software that runs on commodity hardware, with later-stage capital (as Digital Diagnostics' $75M round shows) flowing to whoever proves clinical adoption first.
- Consumer AR/VR headsets gain a second life as medical devices, an outcome that depends on regulatory clearance the corpus does not yet document — the key uncertainty in this structural shift.
The trend: Ophthalmology AI diagnostics is becoming a repeat-funding category where generalist capital firms like D1 back multiple technical routes — dedicated clinic systems and consumer AR/VR headsets alike — betting that software on commodity hardware displaces purpose-built devices.